Article

Pediatric pharmacology of antifungal agents

Current Fungal Infection Reports 04/2012; 2(1):49-56. DOI:10.1007/s12281-008-0008-0

ABSTRACT Pediatric age groups display important differences in host biology, predisposing conditions, epidemiology, and presentation
of fungal infections relative to the adult population. Over the past decade, major advances have been made in the field of
medical mycology. Most importantly, an array of new antifungal agents has entered the clinical arena. Although pediatric approval
of several of these agents remains to be established, the pediatric development of antifungal agents is moving forward. Invasive
fungal infections will remain important causes for morbidity and mortality in immunocompromised pediatric patients. Although
the availability of new therapeutic options is an important advance, antifungal therapy has become increasingly complex, and
a thorough understanding of the available antifungal armamentarium is essential for the successful management of individual
patients.

0 0
 · 
1 Bookmark
 · 
55 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

adult population
 
antifungal agents
 
antifungal therapy
 
available antifungal armamentarium
 
fungal infections
 
host biology
 
immunocompromised pediatric patients
 
major advances
 
medical mycology
 
morbidity
 
new antifungal agents
 
new therapeutic options
 
pediatric approval
 
predisposing conditions
 
thorough understanding
 

Andreas H Groll